Kyle Gano, Chief Business Development Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 3,082 shares at $140.70 ($434K) on 2024-01-31, disclosed to the SEC on 2024-02-02.
Scheduled sale ($434k) by Chief Business Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $140.70 | 1,541 | $217K | 50.0% |
| 2 | $140.70 | 1,541 | $217K | 50.0% |
| Total | $140.70 avg | 3,082 | $434K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $598K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $471K | — | Filing → |